Comparative efficacy of glucagon-like peptide 1 (GLP-1) receptor agonists, pioglitazone and vitamin E for liver histology among patients with nonalcoholic fatty liver disease: systematic review and pilot network meta-analysis of randomized controlled trials. (4th March 2023)
- Record Type:
- Journal Article
- Title:
- Comparative efficacy of glucagon-like peptide 1 (GLP-1) receptor agonists, pioglitazone and vitamin E for liver histology among patients with nonalcoholic fatty liver disease: systematic review and pilot network meta-analysis of randomized controlled trials. (4th March 2023)
- Main Title:
- Comparative efficacy of glucagon-like peptide 1 (GLP-1) receptor agonists, pioglitazone and vitamin E for liver histology among patients with nonalcoholic fatty liver disease: systematic review and pilot network meta-analysis of randomized controlled trials
- Authors:
- Gu, Yunpeng
Sun, Lei
He, Yining
Yang, Luping
Deng, Chaohua
Zhou, Run
Kong, Tingting
Zhang, Wei
Chen, Yutong
Li, Jie
Shi, Junping - Abstract:
- ABSTRACT: Introduction: There is no conclusive evidence comparing the efficacy of glucagon-like peptide 1 (GLP-1) receptor agonists to the other guidelines recommended pharmacotherapy for nonalcoholic fatty liver disease (NAFLD). Therefore, we aim to compare the effects of GLP-1 receptor agonists, pioglitazone and vitamin E in patients with NAFLD. Methods: We searched PubMed, Embase, Web of Science and Cochrane Library up to 11 April 2022. Randomized clinical trials (RCTs) comparing GLP-1 receptor agonists, pioglitazone and vitamin E against placebo or other active controls in patients with NAFLD were included. Results: Nine RCTs including 1482 patients proved eligible. GLP-1 receptor agonists ranked first in steatosis, ballooning necrosis, γ-glutamyl transferase, body weight, body mass index, and triglycerides. Administration of GLP-1 receptor agonists, as compared with placebo, was associated with improvement in liver histology [steatosis (OR = 4.11, 95% CI: 2.83, 5.96), ballooning necrosis (OR = 3.07, 95% CI: 2.14, 4.41), lobular inflammation (OR = 1.86, 95% CI: 1.29, 2.68), fibrosis (OR = 1.52, 95% CI: 1.06, 2.20)]. Conclusions: GLP-1 receptor agonists were as effective as pioglitazone and vitamin E for liver histology among patients with NAFLD. GLP-1 receptor agonists might be considered as an alternative or complementary treatment in the future clinical practice. uf0001
- Is Part Of:
- Expert review of gastroenterology & hepatology. Volume 17:Number 3(2023)
- Journal:
- Expert review of gastroenterology & hepatology
- Issue:
- Volume 17:Number 3(2023)
- Issue Display:
- Volume 17, Issue 3 (2023)
- Year:
- 2023
- Volume:
- 17
- Issue:
- 3
- Issue Sort Value:
- 2023-0017-0003-0000
- Page Start:
- 273
- Page End:
- 282
- Publication Date:
- 2023-03-04
- Subjects:
- Nonalcoholic fatty liver disease -- GLP-1 receptor agonists -- pioglitazone -- vitamin E -- liver histology -- network meta-analysis
Gastroenterology -- Periodicals
Liver -- Diseases -- Periodicals
616.3 - Journal URLs:
- http://www.future-drugs.com/loi/egh ↗
https://www.tandfonline.com/toc/ierh20/current ↗
http://informahealthcare.com ↗ - DOI:
- 10.1080/17474124.2023.2172397 ↗
- Languages:
- English
- ISSNs:
- 1747-4124
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 9830.067000
British Library DSC - BLDSS-3PM
British Library HMNTS - Digital store
British Library HMNTS - ELD Digital store - Ingest File:
- 26064.xml